Tumor Differentiation as a Prognostic Marker in Clinically Staged T1bN0 Esophageal Adenocarcinoma

Ofer Margalit; Einat Shacham-Shmueli; Gal Strauss; Yu Xiao Yang; Yaacov R. Lawrence; Alon Ben Nun; Idan Levy; Kim A. Reiss; Talia Golan; Naama Halpern; Dan Aderka; Bruce Giantonio; Ronac Mamtani; Ben Boursi

doi:10.1080/07357907.2023.2255907

Tumor Differentiation as a Prognostic Marker in Clinically Staged T1bN0 Esophageal Adenocarcinoma

Ofer Margalit^*, Einat Shacham-Shmueli, Gal Strauss, Yu Xiao Yang, Yaacov R. Lawrence, Alon Ben Nun, Idan Levy, Kim A. Reiss, Talia Golan, Naama Halpern, Dan Aderka, Bruce Giantonio, Ronac Mamtani, Ben Boursi

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Current guidelines recommend that clinically staged T1N0 esophageal cancers are to be referred to surgery or endoscopic resection. Using the National Cancer Database, we identified 733 individuals with clinically staged T1N0 esophageal carcinoma, who underwent upfront surgery and did not receive any prior treatment. We assessed upstaging, which was defined as ≥ T2 disease or positive lymph nodes. Poorly differentiated adenocarcinomas were associated with upstaging, whereas squamous cell carcinomas were not. Specifically, the percentage of upstaging among individuals with clinically staged T1b and poorly differentiated tumor was 33.8%. Therefore, clinically staged T1bN0 poorly differentiated esophageal adenocarcinomas are at high risk for upstaging following surgery.

Original language	English
Pages (from-to)	734-738
Number of pages	5
Journal	Cancer Investigation
Volume	41
Issue number	8
DOIs	https://doi.org/10.1080/07357907.2023.2255907
State	Published - 2023

Keywords

Esophageal adenocarcinoma
misclassification
prognostic marker
stage T1b
tumor differentiation

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/07357907.2023.2255907

Cite this

Margalit, O., Shacham-Shmueli, E., Strauss, G., Yang, Y. X., Lawrence, Y. R., Ben Nun, A., Levy, I., Reiss, K. A., Golan, T., Halpern, N., Aderka, D., Giantonio, B., Mamtani, R., & Boursi, B. (2023). Tumor Differentiation as a Prognostic Marker in Clinically Staged T1bN0 Esophageal Adenocarcinoma. Cancer Investigation, 41(8), 734-738. https://doi.org/10.1080/07357907.2023.2255907

@article{d0bca22b078f42cf9172faf9e72a530f,

title = "Tumor Differentiation as a Prognostic Marker in Clinically Staged T1bN0 Esophageal Adenocarcinoma",

abstract = "Current guidelines recommend that clinically staged T1N0 esophageal cancers are to be referred to surgery or endoscopic resection. Using the National Cancer Database, we identified 733 individuals with clinically staged T1N0 esophageal carcinoma, who underwent upfront surgery and did not receive any prior treatment. We assessed upstaging, which was defined as ≥ T2 disease or positive lymph nodes. Poorly differentiated adenocarcinomas were associated with upstaging, whereas squamous cell carcinomas were not. Specifically, the percentage of upstaging among individuals with clinically staged T1b and poorly differentiated tumor was 33.8%. Therefore, clinically staged T1bN0 poorly differentiated esophageal adenocarcinomas are at high risk for upstaging following surgery.",

keywords = "Esophageal adenocarcinoma, misclassification, prognostic marker, stage T1b, tumor differentiation",

author = "Ofer Margalit and Einat Shacham-Shmueli and Gal Strauss and Yang, {Yu Xiao} and Lawrence, {Yaacov R.} and {Ben Nun}, Alon and Idan Levy and Reiss, {Kim A.} and Talia Golan and Naama Halpern and Dan Aderka and Bruce Giantonio and Ronac Mamtani and Ben Boursi",

note = "Publisher Copyright: {\textcopyright} 2023 The Author(s). Published with license by Taylor & Francis Group, LLC.",

year = "2023",

doi = "10.1080/07357907.2023.2255907",

language = "אנגלית",

volume = "41",

pages = "734--738",

journal = "Cancer Investigation",

issn = "0735-7907",

publisher = "Informa Healthcare",

number = "8",

}

Margalit, O , Shacham-Shmueli, E, Strauss, G, Yang, YX, Lawrence, YR , Ben Nun, A, Levy, I, Reiss, KA, Golan, T , Halpern, N , Aderka, D, Giantonio, B, Mamtani, R & Boursi, B 2023, 'Tumor Differentiation as a Prognostic Marker in Clinically Staged T1bN0 Esophageal Adenocarcinoma', Cancer Investigation, vol. 41, no. 8, pp. 734-738. https://doi.org/10.1080/07357907.2023.2255907

TY - JOUR

T1 - Tumor Differentiation as a Prognostic Marker in Clinically Staged T1bN0 Esophageal Adenocarcinoma

AU - Margalit, Ofer

AU - Shacham-Shmueli, Einat

AU - Strauss, Gal

AU - Yang, Yu Xiao

AU - Lawrence, Yaacov R.

AU - Ben Nun, Alon

AU - Levy, Idan

AU - Reiss, Kim A.

AU - Golan, Talia

AU - Halpern, Naama

AU - Aderka, Dan

AU - Giantonio, Bruce

AU - Mamtani, Ronac

AU - Boursi, Ben

PY - 2023

Y1 - 2023

N2 - Current guidelines recommend that clinically staged T1N0 esophageal cancers are to be referred to surgery or endoscopic resection. Using the National Cancer Database, we identified 733 individuals with clinically staged T1N0 esophageal carcinoma, who underwent upfront surgery and did not receive any prior treatment. We assessed upstaging, which was defined as ≥ T2 disease or positive lymph nodes. Poorly differentiated adenocarcinomas were associated with upstaging, whereas squamous cell carcinomas were not. Specifically, the percentage of upstaging among individuals with clinically staged T1b and poorly differentiated tumor was 33.8%. Therefore, clinically staged T1bN0 poorly differentiated esophageal adenocarcinomas are at high risk for upstaging following surgery.

AB - Current guidelines recommend that clinically staged T1N0 esophageal cancers are to be referred to surgery or endoscopic resection. Using the National Cancer Database, we identified 733 individuals with clinically staged T1N0 esophageal carcinoma, who underwent upfront surgery and did not receive any prior treatment. We assessed upstaging, which was defined as ≥ T2 disease or positive lymph nodes. Poorly differentiated adenocarcinomas were associated with upstaging, whereas squamous cell carcinomas were not. Specifically, the percentage of upstaging among individuals with clinically staged T1b and poorly differentiated tumor was 33.8%. Therefore, clinically staged T1bN0 poorly differentiated esophageal adenocarcinomas are at high risk for upstaging following surgery.

KW - Esophageal adenocarcinoma

KW - misclassification

KW - prognostic marker

KW - stage T1b

KW - tumor differentiation

UR - http://www.scopus.com/inward/record.url?scp=85171690117&partnerID=8YFLogxK

U2 - 10.1080/07357907.2023.2255907

DO - 10.1080/07357907.2023.2255907

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 37665657

AN - SCOPUS:85171690117

SN - 0735-7907

VL - 41

SP - 734

EP - 738

JO - Cancer Investigation

JF - Cancer Investigation

IS - 8

ER -

Tumor Differentiation as a Prognostic Marker in Clinically Staged T1bN0 Esophageal Adenocarcinoma

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this